10h agoThe FlyBEARISH 34Analyst
Archived explainer. For the current picture see today's AVBP page.
Why Is ARRIVENT BIOPHARMA I (AVBP) Stock Down Today?
By the Top Tier Newswire AI Desk · October 7, 2026 at 12:03 AM ET · reviewed against 18 wire stories
ARRIVENT BIOPHARMA I (AVBP) is down -46.98% in the latest session. Our newswire has captured 18 stories on AVBP across 11 sources in the last 36 hours, with AI sentiment reading bearish (avg 29/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
AVBP stock is down 46.98% at $15.09 following the announcement that its experimental lung cancer treatment failed to meet its primary endpoint in a Phase 3 trial. This development has triggered a wave of downgrades and lowered price targets from analysts, contributing to a sharp sell-off. The stock is now near its 52-week low, reflecting the market's negative reaction to the clinical setback.
What Happened
ArriVent Biopharma's Firmonertinib failed its primary endpoint in the Phase 3 FURVENT trial, which significantly weakened the investment case for the company. The drug's failure to meet the trial's primary endpoint of blinded independent central review progression-free survival (BICR PFS) has led to a reassessment of its potential. Despite showing encouraging investigator-assessed efficacy, the setback has raised concerns about the drug's future and the company's prospects. As a result, multiple analysts have cut their price targets, including Clear Street, Jefferies, Truist, and Jones, with targets reduced to as low as $18 from previous levels as high as $47.
What The Data Shows
The stock has fallen by 47.0% over the last eight sessions, from $28.45 to $15.09. On October 6, the stock printed four fresh 52-week lows, indicating continued weakness. The stock currently trades near its 52-week low of $12.09 and has a market capitalization of $1.4 billion. ArriVent remains unprofitable, with a trailing twelve-month earnings per share (EPS) of -3.70. The stock has a beta of 1.36, suggesting higher volatility compared to the broader market.
What To Watch
Investors should monitor the company's next steps following the trial's failure, including any strategic adjustments or new data releases. ArriVent has not announced an upcoming earnings date, so coverage breadth and further analyst commentary will be key indicators of the stock's near-term trajectory.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
AVBP by the numbers
Last: $15.09Session: -46.98%7 sessions: -46.96%Coverage: 18 stories / 11 sourcesAI sentiment: 29/100 (bearish)Mkt cap: $1.4B52w: $17.00 to $35.83
The headlines behind the move
11h agoPR NewswireBEARISH 22General
ArriVent BioPharma Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into ArriVent BioPharma (AVBP)
AVBP shareholders are holding stock near a $12.09 52-week low after the Phase 3 FURVENT trial missed its primary endpoint, just five months after ArriVent launched a $250 million at-the-market stock offering. NEW YORK, Oct. 6, 2026 /PRNewswire/ -- A 56.7% premarket plunge hit AVBP...
11h agoSeeking AlphaBEARISH 22Product/PR
ArriVent BioPharma: Phase 3 Failure Resets The Investment Case (Rating Downgrade)
ArriVent's Firmonertinib failed its primary BICR PFS endpoint despite encouraging investigator-assessed efficacy, weakening the outlook. Read more on AVBP.
13h agoThe FlyBEARISH 34Analyst
ArriVent Biopharma price target lowered to $22 from $45 at Jones
13h agoThe FlyBEARISH 28Analyst
ArriVent Biopharma price target lowered to $18 from $45 at Truist
14h agoThe FlyBEARISH 34Analyst
ArriVent Biopharma price target lowered to $18 from $45 at Jefferies
15h agoStocktwits NewsBEARISH 22Product/PR
AVBP Stock Crashes More Than 48% To All-Time Low After Lung Cancer Trial Setback – Retail Calls It ‘Way Undervalued’
ArriVent BioPharma’s experimental lung cancer treatment failed to meet its primary endpoint in a Phase 3 trial.
17h agoBarron'sBEARISH 12Earnings
Why This Biotech Stock Is Having Its Worst Day Ever
ArriVent Biopharma said its lung-cancer drug failed to meet long-term goals.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on AVBP: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier AVBP move explainers: 2026-10-07 · 2026-10-06